The PATH Center for Vaccine Innovation and Access (CVIA) spans every stage of vaccine research, development, and introduction to make lifesaving vaccines widely available to women, children, and communities around the globe.
Vaccines are one of the most successful, cost effective solutions available to ensure children, no matter where they’re born, not only survive, but can thrive and reach their full potential. That’s why we work to accelerate the development and introduction of lifesaving vaccines around the world.
CVIA focuses its efforts across four disease areas: malaria; enteric and diarrheal diseases; respiratory infections and maternal immunization; and zoonotic, emerging, and infectious diseases. Our portfolio encompasses more than two dozen vaccine projects in development and use across 18 different diseases, with an emphasis on the world’s leading infectious causes of childhood deaths: diarrheal disease, pneumonia, and malaria.
But it takes a lot to move a vaccine from an idea into a safe and effective tool used to prevent disease. It’s even more challenging when the diseases disproportionately impact young children and women in low-resource settings. CVIA builds on more than 20 years of PATH’s success in developing and introducing vaccines to improve health for those living in some of most heavily burdened and hardest to reach places. We bring together multi-disciplinary expertise across the entire vaccine development and delivery spectrum—from early-stage research to innovative approaches for new vaccine introduction and everything in between.
Our success in vaccine innovation depends on our country-centered approach and deep engagement with multiple partners, including immunization program managers and ministries of health to provide crucial insights; scientists and clinical researchers to develop and evaluate novel approaches to vaccines in real-world conditions; manufacturers to accelerate development; global agencies like the World Health Organization and UNICEF; financing bodies like Gavi, the Vaccine Alliance; and governments to support immunization implementation. We work with communities to understand their needs and priorities and commit to pricing and distribution strategies that ensure accessibility, availability, affordability, acceptability, and sustainability.
Some of CVIA’s successes include:
CVIA projects are currently supported by grants from numerous funders, including the Bill & Melinda Gates Foundation, the US Department of Health and Human Services, and the United Kingdom’s Department for International Development.
Dr. David Kaslow
Vice President, Essential Medicines. Director, Center for Vaccine Innovation and Access
Director, Office of Essential Medicines
Global Human Resources Director, Essential Medicines
Dr. Bruce Innis
Global Head, Respiratory Infections & Maternal Immunization, CVIA
Dr. Ashley Birkett
Global Head, Malaria, Center for Vaccine Innovation and Access
Dr. Fred Cassels
Global Head, Enteric and Diarrheal Diseases, Center for Vaccine Innovation and Access
Dr. Debbie Atherly
Global Head, Policy Access and Introduction, Center for Vaccine Innovation and Access
Dr. Jorge Flores
Global Head, Clinical and Regulatory Affairs, Center for Vaccine Innovation and Access
Dr. John Konz
Leader, Integrated Portfolio and Financial Management, Center for Vaccine Innovation and Access
Global Head, Finance and Contract Management, Center for Vaccine Innovation and Access
Dr. Margaret Wecker
Global Head, Regulatory, Center for Vaccine Innovation and Access
Program Leader, Medical Devices and Health Technologies